Quick Answer
Pyxis Oncology, Inc. reported Common Stock Shares Outstanding of 62.69 million shares for the year ending 2025.
- Pyxis Oncology, Inc. showed an increase of +4.5% in Common Stock Shares Outstanding from 2024 to 2025.
- This data is from Pyxis Oncology, Inc.'s annual report (Form 10-K), filed with the SEC on March 23, 2026.
- XBRL data for this metric is available from 2020 to 2025 (6 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q3 2021: 1.64 million shares | Q1 2022: 32.37 million shares | Q2 2022: 32.48 million shares | Q3 2022: 32.59 million shares | Q1 2023: 36.92 million shares | Q2 2023: 39.38 million shares | Q3 2023: 44.29 million shares | Q1 2024: 58.80 million shares | Q2 2024: 58.91 million shares | Q3 2024: 59.45 million shares | Q1 2025: 61.63 million shares | Q2 2025: 62.02 million shares | Q3 2025: 62.15 million shares.
- Over the full 6 years of available data (2020 to 2025), Pyxis Oncology, Inc.'s Common Stock Shares Outstanding has grown by 4,762.2%.
- Historical annual values: Fiscal year 2025: 62.69 million shares | Fiscal year 2024: 59.97 million shares | Fiscal year 2023: 44.75 million shares | Fiscal year 2022: 34.96 million shares | Fiscal year 2021: 32.22 million shares | Fiscal year 2020: 1.29 million shares.
- Data sourced from SEC EDGAR public filings as of August 9, 2026.
Last verified: